May 19, 2021
PAR-21-183 - Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
National Institute on Drug Abuse (NIDA)
The National Institute on Drug Abuse (NIDA) will host an informational webinar to provide information and respond to questions from prospective applicants who may be interested in submitting grant applications in response to the Funding Opportunity Announcement (FOA) PAR-21-183 - Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
The purpose of the FOA is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. FDA authorization of DTx can play an important role in increasing the availability of treatments to patients with SUD.The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.
The webinar will take place on Monday, June 7th, 2021 at 2:00 PM United States Eastern Standard Time (EST).
To join the meeting:
To join this webinar, please visit this link.
Meeting ID: 160 470 9010 Passcode: 174235
To join by phone, please dial:
+16692545252, passcode: *174235# US or
+16468287666 passcode: *174235# US
Participation in the webinar, although encouraged, is optional and is not required for the submission of an application. Advanced registration is not required. You may send questions ahead of the webinar to the Scientific/Research contact listed below.
This webinar will be recorded and a video with captioning will be available after the event upon request to Dr. Kevin Walton at firstname.lastname@example.org.